Forte Biosciences Inc. (FBRX)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
16.55
1.93 (13.20%)
At close: Jan 15, 2025, 1:43 PM
Company Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata.
The company is headquartered in Dallas, Texas.
Forte Biosciences Inc.
Country | United States |
IPO Date | Apr 13, 2017 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 11 |
CEO | Dr. Paul A. Wagner Ph.D. |
Contact Details
Address: 3060 Pegasus Park Drive Dallas, Texas United States | |
Website | https://www.fortebiorx.com |
Stock Details
Ticker Symbol | FBRX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001419041 |
CUSIP Number | 34962G109 |
ISIN Number | US34962G1094 |
Employer ID | 26-1243872 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Paul A. Wagner Ph.D. | Chief Executive Officer, President & Chairman |
Antony A. Riley CPA | Chief Financial Officer |
Christopher Roenfeldt | Chief Operating Officer |
Dr. Barbara K. Finck M.D. | Chief Medical Clinician & Director |
Steven Ruhl | Chief Technical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 10, 2025 | SCHEDULE 13G | Filing |
Jan 02, 2025 | 4 | Filing |
Jan 02, 2025 | 4 | Filing |
Dec 31, 2024 | DEF 14A | Filing |
Dec 20, 2024 | 424B3 | Filing |
Dec 13, 2024 | S-3 | Filing |
Dec 06, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Dec 03, 2024 | 8-K | Current Report |
Nov 22, 2024 | 4 | Filing |
Nov 20, 2024 | 8-K | Current Report |